UNSPSC 51161715: Dimefline

This classification denotes a cns stimulant with the molecular formula C20H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9WII5M0DU3, chemically known as 4h-1-benzopyran-4-one, 8-((dimethylamino)methyl)-7-methoxy-3-methyl-2-phenyl- (9ci) but generally known as dimefline, which bears US NIH Compound Identifier 3078. European Medicines Agency schedules Dimefline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07156MIG.

UNSPSC 51161715 Dimefline, a Commodity code, does not align with the state and local procurement activity tagged under it. The recent solicitations in this code's record—naloxone and drug deactivation systems, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals—concern pharmaceutical procurement, pharmacy benefit management, and naloxone distribution, none of which match the pharmaceutical compound dimefline. The code shows little relevant recent activity that maps to its nominal scope.

Activity does appear across multiple issuing-body types and states. Seminole County, Florida issued an IFB on June 30, 2026 (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually; Hall County, Georgia issued an RFQ/P on May 4, 2026 (due June 4, 2026) for on-site pharmacy services at its Family Health Center in Gainesville; Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore direct-to-manufacturer prescription contracting; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. The geographic spread spans Florida, Georgia, Texas, and the upper Midwest, though the code's tagging appears to be a classification error rather than genuine commodity alignment.